Convergent Autophagy-Lysosome Pathway Therapeutics Across Neurodegenerative Diseases

Impaired autophagy-lysosome function is a convergent mechanism across neurodegenerative diseases, making pathway-level intervention attractive. However, nodes of failure differ: CMA (LAMP2A) declines in PD, bulk autophagy (Beclin-1) is impaired in AD, and lysosomal biogenesis (TFEB) shows compensatory increases in some contexts. Identifying the most disease-agnostic node guides drug development.

$2.2M

OPEN

Confidence:

73%

Created: 2026-04-17

Linked Knowledge Gap

Autophagy-lysosome pathway convergence across neurodegenerative diseases

Multiple NDDs converge on autophagy-lysosome dysfunction. Are there universal therapeutic targets?

Status: partially_addressed Priority: 0.87 Domain: neurodegeneration

Scoring Dimensions

Gap Importance0.87

Therapeutic Potential0.82

Investment Level0.00

Urgency0.79

Landscape Score0.70

Composite Score 0.800

Linked Targets (1)

TFEB TFEB Protein PDB:5HQB0.34

🧬 View 3D Structure — PDB 5HQB click to expand

Detected Targets:

TFEB

3D Protein Structure

▶ View 3D structure: TFEB — PDB 4NTI

Experimental structure from RCSB PDB | Powered by Mol* | Rotate: click+drag | Zoom: scroll

Landscape analysis not yet run for this challenge. Run the landscape analyzer to get competitive intelligence.

Linked Hypotheses (4)

Transcriptional Autophagy-Lysosome Coupling FOXO10.88 Autophagosome Maturation Checkpoint Control STX170.71 Lysosomal Enzyme Trafficking Correction IGF2R0.71 Lysosomal Calcium Channel Modulation Therapy MCOLN10.70